We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+32.04%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.4B
AUM Growth
+$1.66B
Cap. Flow
+$453M
Cap. Flow %
7.07%
Top 10 Hldgs %
53.23%
Holding
81
New
14
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$98.5M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$88.5M
3
CRGX
CARGO Therapeutics
CRGX
+$87.8M
4
ALKS icon
Alkermes
ALKS
+$78.3M
5
ARGX icon
argenx
ARGX
+$74.6M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$116M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$28.5M
3
ILMN icon
Illumina
ILMN
+$25.8M
4
AXNX
Axonics, Inc. Common Stock
AXNX
+$24.8M
5
SCPH
scPharmaceuticals
SCPH
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWAV
51
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$12.4M 0.19%
65,060
-58,940
-48% -$11.1M
TRML
52
DELISTED
Tourmaline Bio
TRML
$10.4M 0.16%
+398,850
New +$7.98M
ACET icon
53
Adicet Bio
ACET
$74.7M
$7.81M 0.12%
258,414
-6,678
-3% -$146K
SLRN
54
DELISTED
ACELYRIN
SLRN
$7.3M 0.11%
978,310
– –
IMUX icon
55
Immunic
IMUX
$195M
$6.5M 0.1%
433,526
– –
CUTR
56
DELISTED
Cutera, Inc.
CUTR
$6.41M 0.1%
1,817,585
-29,011
-2% -$88.4K
SABS icon
57
SAB Biotherapeutics
SABS
$355M
$6.31M 0.1%
+917,828
New +$7.7M
MIST icon
58
Milestone Pharmaceuticals
MIST
$152M
$5.44M 0.08%
3,256,102
– –
XGN icon
59
Exagen
XGN
$166M
$2.99M 0.05%
1,504,602
+12,170
+0.8% +$21K
APYX icon
60
Apyx Medical
APYX
$171M
$2.69M 0.04%
1,025,963
-751,231
-42% -$1.82M
ARYD
61
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.39M 0.02%
127,970
– –
SGHT icon
62
Sight Sciences
SGHT
$412M
$850K 0.01%
+164,806
New +$509K
RCKTW icon
63
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$172K ﹤0.01%
350,000
– –
SIEN
64
DELISTED
Sientra, Inc.
SIEN
$49.4K ﹤0.01%
81,016
-223,020
-73% -$249K
AKYA
65
DELISTED
Akoya BioSciences
AKYA
– –
-338,422
Closed -$1.57M
DSGN icon
66
Design Therapeutics
DSGN
$876M
– –
-2,512,986
Closed -$5.93M
ILMN icon
67
Illumina
ILMN
$28.4B
– –
-193,393
Closed -$25.8M
MLTX icon
68
MoonLake Immunotherapeutics
MLTX
$1.55B
– –
-500,000
Closed -$28.5M
MLYS icon
69
Mineralys Therapeutics
MLYS
$2.41B
– –
-922,100
Closed -$8.77M
OM icon
70
Outset Medical
OM
$90.8M
– –
-53,911
Closed -$8.8M
PMVP icon
71
PMV Pharmaceuticals
PMVP
$63.5M
– –
-2,375,785
Closed -$14.6M
RLMD icon
72
Relmada Therapeutics
RLMD
$527M
– –
-2,131,835
Closed -$6.4M
SCPH
73
DELISTED
scPharmaceuticals
SCPH
– –
-3,297,843
Closed -$23.5M
SGMT icon
74
Sagimet Biosciences
SGMT
$559M
– –
-400,277
Closed -$3.52M
SYK icon
75
Stryker
SYK
$130B
– –
-28,000
Closed -$7.65M
1 2
3
4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2023 Portfolio in Review

As of Q4 2023, RTW Investments held 81 positions worth $6.4B, up 35% from $4.74B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

RTW Investments deployed $453M of net new capital in Q4 2023, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Arvinas: 4,213,483 shares worth $173M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $116M trimmed.

  • RTW Investments's largest Q4 2023 buy was Arvinas: 4,213,483 shares worth $173M.
  • RTW Investments added most to Madrigal Pharmaceuticals in Q4 2023, an estimated $88.5M increase.
  • RTW Investments's biggest Q4 2023 reduction was Thermo Fisher Scientific, cutting an estimated $116M.
  • RTW Investments fully exited MoonLake Immunotherapeutics in Q4 2023, selling an estimated $28.5M.
  • RTW Investments's ten largest holdings make up 53% of its $6.4B portfolio in Q4 2023.
  • RTW Investments opened 14 new positions and closed 17 in Q4 2023.
  • RTW Investments's portfolio value rose 35% quarter-over-quarter to $6.4B.

Based on RTW Investments's 13F filing for Q4 2023, filed 14 Feb 2024.